Drawing for EP EVIDENCE LEADER

USPTO serial 86720788

EP EVIDENCE LEADER

Reviewed by CopyMark Law Group

Reg. 4958856Status 710
Filing date
Status date
Registration date
May 17, 2016
Examiner
YOUNG, THOMAS PAUL
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with EP EVIDENCE LEADER?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
041Providing an Internet website portal featuring links to publications of others in the field of arrhythmia research and heart failure device technology researchSECTION 8 - CANCELLEDJul 16, 2015

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 2, 2022C8..CANCELLED SEC. 8 (6-YR)—
May 17, 2021REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 17, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 1, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 1, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 10, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 27, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 27, 2016XAECEXAMINER'S AMENDMENT ENTERED—
Jan 27, 2016GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 27, 2016GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 27, 2016CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 27, 2016XAECEXAMINER'S AMENDMENT ENTERED—
Jan 27, 2016GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 27, 2016GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 27, 2016CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 21, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 20, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 20, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 20, 2016TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 8, 2015GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Oct 8, 2015GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Oct 8, 2015EPENCOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY—
Oct 8, 2015CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Oct 6, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Oct 6, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 6, 2015GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 6, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 5, 2015DOCKASSIGNED TO EXAMINER—
Aug 14, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 14, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance